This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00473/identifier/drugbank/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00473/identifier/chemspider/
n18http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00473/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00473/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00473/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00473/identifier/bindingdb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00473/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00473/identifier/pubchem-substance/

Statements

Subject Item
n2:DB00473
rdf:type
n3:Drug
n3:description
Hexylcaine hydrochloride, also called cyclaine (Merck) or osmocaine, is a short-acting local anesthetic. It acts by inhibiting sodium channel conduction. Overdose can lead to headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function. Hexylcaine has been discontinued in the US market.
n3:group
approved withdrawn
n3:halfLife
<10 minutes
n3:indication
Used as a local anesthetic for surface application, infiltration or nerve block
n3:manufacturer
n9:271B5905-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00473 n18:DB00473
dcterms:title
Hexylcaine
adms:identifier
n7:PA164746489 n8:Hexylcaine n10:10770 n11:46506241 n12:DB00473 n13:C14172 n14:50017670 n15:10315
n3:mechanismOfAction
Hexyl caine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel.
n3:synonym
Cyclaine Hexylcainum Hexylcaine Hexilcaina
n3:toxicity
Symptoms of anesthetic overdose include headache, tinnitus, circumoral and tongue paresthesias, restlessness, talkativeness, facial twitching, convulsions, respiratory arrest, and cardiac depression
n3:salt
n3:synthesisReference
U.S. Patent 2,486,374.
n3:IUPAC-Name
n4:271B590A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5910-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B590F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B590C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B590D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B590E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5908-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5920-363D-11E5-9242-09173F13E4C5 n4:271B5906-363D-11E5-9242-09173F13E4C5 n4:271B5909-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5907-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5916-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5917-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5911-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5912-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5914-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5913-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5915-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
532-77-4
n3:category
n3:Bioavailability
n4:271B591B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B591D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B591E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B591F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B591A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5919-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B591C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B590B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5918-363D-11E5-9242-09173F13E4C5